| Abstrakt: |
The World Health Organization (WHO) has included three disease-modifying therapies (DMTs) for multiple sclerosis (MS) on its Essential Medicines List (EML), which is a significant milestone for people with MS worldwide. However, implementing the EML into local practice, especially in low-income countries, poses challenges. The Intersectoral Global Action Plan (IGAP) provides a roadmap for addressing these challenges, as demonstrated in the case of epilepsy treatment. Collaborative efforts between stakeholders, including clinicians, researchers, policy makers, and patient groups, are necessary for successful implementation. Prioritizing MS in national health systems, ensuring standard of care, and improving access, funding, and reimbursement are recommended actions. International and regional organizations can support advocacy efforts and facilitate learning between countries. The time for action to improve care and access to treatment for neurological diseases is now. [Extracted from the article] |
